YB-811

YB-811 is a novel antibody-drug conjugate (ADC) developed by Ymmunobio AG that targets the human neuronal pentraxin receptor (NPTXR). NPTXR is a type II transmembrane protein typically involved in trans-synaptic organization in the brain but is highly expressed in various solid tumors, including bladder, cervical, non-triple-negative breast (non-TNBC), non-small cell lung (NSCLC), and pancreatic cancers, while remaining absent in healthy non-neuronal tissues. YB-811 utilizes a fully humanized monoclonal antibody (YB-800) conjugated to two distinct payloads: four molecules of monomethylauristatin F (MMAF) via non-cleavable linkers and four molecules of exatecan via cleavable linkers. This dual-payload strategy is designed to enhance efficacy and overcome resistance. Preclinical studies have demonstrated significant anti-tumor activity and tumor regression in experimental models.